Piramal Pharma to expand with Rs 1,000 cr outlayIllustrative image – not actual.

Piramal Pharma (PPL) plans to invest around Rs 1,000 crore over the next 18 months for growth through brownfield expansion and consolidation purposes.

For the second half of the financial year (FY), the company would deploy around Rs 330 crore to achieve operational excellence, and make the added brownfield capacities more productive.

In the first half of the current FY, the Mumbai-based pharma company witnessed growth across its three operational verticals- contract development and manufacturing organisation (CDMO), complex hospital generics (CHG), and India consumer healthcare (ICH), all of which have reported double-digit growth.

PPL is also consolidating its CDMO businesses through acquisitions and partnerships. The company's investment roadmap includes Hemmo Pharmaceuticals for Rs 775 crore, a 27.78 percent stake in Yapan Bio worth Rs 101.7 crore, and a joint venture with Allergan.

The company continues to expand in its verticals through sustainable growth, along with quality manufacturing, and compliance as key differentiators.

The company recently raised Rs 1,050 crore through a rights issue, primarily used for debt repayment. However, a portion of this fund has also been allocated for capital expenditure. 
 

← All latest storiesBack to top →